C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD, discusses the use of MRD as an early end point in a study evaluating daratumumab plus KRd in newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD, discussed the benefit of Dara-KRd in patients with multiple myeloma stratified by transplant eligibility, risk, and age.

C. Ola Landgren, MD, PhD, discusses the rapidly changing treatment paradigm within multiple myeloma.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

C. Ola Landgren, MD, PhD, discusses novel therapeutic approaches that are generating excitement in multiple myeloma.

Ola Landgren, MD, PhD, discusses the rationale behind examining whole-genome sequencing in smoldering myeloma.

C. Ola Landgren, MD, PhD, discusses the efficacy of idecabtagene vicleucel in the treatment of patients with relapsed/refractory myeloma.

C. Ola Landgren, MD, PhD, discusses investigational cellular therapies in multiple myeloma.

C. Ola Landgren, MD, PhD, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the superiority of 3-drug regimens and the next steps in the treatment of patients with multiple myeloma.

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses using daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the triplet of daratumumab, bortezomib, and dexamethasone in the treatment of patients with relapsed myeloma.

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses unanswered questions following the results of the phase III POLLUX and CASTOR studies, which explored the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone, respectively.

C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.

C. Ola Landgren, MD, PhD, from the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with multiple myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.